About Pipeline Strategy Events Investors News Contact
 
  investors  
  On July 1, 2010, ACT successfully completed raising $10 million, which was six (6) months ahead of its planned schedule for 2010. Funds from this capital raise will be used diligently to advance into Phase 1 human clinical trials one or more of the five (5) products it has exclusively licensed from UofL's James Graham Brown Cancer Center.

ACT intends to efficiently deploy these funds to advance one or more compounds from its product pipeline up to or through Phase 1 human clinical trials and then explore strategic partnering options with leading pharmaceutical and biotechnology companies.